Macrocyclic mcl-1 inhibitors and methods of use

The present disclosure provides for compounds of formula (I)wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment...

Full description

Saved in:
Bibliographic Details
Main Authors TAO Zhi-Fu, LAI Chunqui, MASTRACCHIO Anthony, POHLKI Frauke, SONG Xiaohong, DOHERTY George, WANG Xilu, SOUERS Andrew, JUDD Andrew, TESKE Jesse, JI Cheng, KLING Andreas, WENDT Michael, JANTOS Katja, PENNING Thomas, BRAJE Wilfried, SULLIVAN Gerard, KUNZER Aaron
Format Patent
LanguageEnglish
Hebrew
Published 31.03.2020
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides for compounds of formula (I)wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
Bibliography:Application Number: IL20200272681